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Abstract
Systemic lupus Erythematosus (SLE) is a chronic multi-system autoimmune disease that
can affect a person’s physical, mental, and social life. It imposes a substantial economic bur-
den up on patients, carers, healthcare systems, and wider society. This is the first study to
examine the direct health care costs of SLE in Alberta using real-world data. Alberta main-
tains a publicly funded, universally available health care system. Health service use and
direct healthcare costs of SLE and non-SLE cases were determined from inpatient hospital
services, fee-for-physician services, emergency services, and ambulatory care services. All
costs were estimated for calendar year 2016. Data were analysed using central measures
specifically the mean to determine the annual costs of SLE and non-SLE. A total number of
10,932 (Male = 2,546; Female = 8,386), and 41,851,36 (Male = 21,157,76; Female =
20,693,60) of SLE and non-SLE cases, respectively were included in this study. The mean
annual costs of SLE, and non-SLE per case were $7,740.19 (Male = $7,986.59; Female =
$7,665.38), and $2,479.53 (Male = $2,265.57; Female = $2,698.30), (p < 0.001) respec-
tively. The mean annual costs of fee-for-physician services (SLE = $2,160.03; non-SLE =
$840.00) (p < 0.001), inpatient hospital services (SLE = $3,462.86; non-SLE = $1,007.29),
(p < 0.001) emergency services (SLE = $440.28; non-SLE = $176.65), (p < 0.001) and
ambulatory care services (SLE = $1,677.03; non-SLE = $455.05) (p < 0.001) per case were
estimated. The findings showed that the costs of SLE were considerably high for patients
and healthcare system. This highlights the importance of appropriate treatment and man-
agement of SLE. Further studies are required to fully investigate both the direct and indirect
economic burden of SLE including out-of-pocket expenses, costs to patients and caregivers
and productivity loss.
Introduction
Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease that affects
multiple organ systems in the body, and is a cause of physical and functional disability [1].
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Although SLE is an extremely heterogeneous disease in terms of progression or development,
its prevalence, incidence, and socioeconomic impact is substantial. Evidence from the Michi-
gan Lupus Epidemiology and Surveillance Programme suggested a prevalence of 72.8 and inci-
dence of 5.5 SLE per 100,000 population per year [2]. Other studies have also reported the
incidence of SLE of 1.0 per 100,000 per year in Denmark [3]; and 4.43 per 1,000,000 in Alberta
[4]. Environmental factors contributing to the development of SLE include cigarette smoking,
and exposure to silica, pollution, and/or solvents [5]. The severe manifestation and unpredict-
able experience of patients with SLE may result to substantial healthcare resource utilization.
This is associated with fee for physician visits and other healthcare professionals, diagnostic
tests, procedures, hospitalizations, medications, and costs that result from loss of employment
and diminished work productivity [6].
The diverse manifestation of SLE and its treatment may incur a substantial direct and indi-
rect costs to patients with these conditions. For example, the total direct costs of SLE per
patient per year in Taiwan [7], South Korea [8], Germany [9], and the United States of Amer-
ica (USA) [10] were estimated as $1,847, $4,940, $4,887, and $5,457, respectively. The annual
indirect costs of SLE per patient have been estimated in the United Kingdom [11], Sweden
[12], and Germany [9] as $12,309, $20,046, and $17,184, respectively. The mean annual direct
costs estimate of SLE per patient in Canada was $5,062 [13]. Of this annual direct costs of SLE
in Canada, the contribution of health professional visit, emergency room visit, diagnostic pro-
cedure, outpatient surgery, and inpatient care was $893, $1,058, $605, $126, and $2,404,
respectively.
The previous published study of the costs of SLE in Canada estimated the costs of SLE via
questionnaire survey with limited sample size. The use of questionnaire can either over or
underestimate the costs associated with SLE and as such may not be generalizable in the real-
world. In addition, no previous studies have compared the costs of SLE with those of non-SLE
case. This study examined the direct health care costs of SLE, compared to non-SLE cases for
inpatient hospital services, fee-for-physician services, emergency department services, and
ambulatory care services in the real-world in Canada. Studies conducted using real-world data
from a variety of sources such as electronic health records, claims and billing activities, claims
and billing data, and disease registries are believed to solve the problem of generalizability.
Materials and methods
The province of Alberta, Canada maintains a publicly funded, universally available healthcare
system. All residents of the province are required, by law, to register with the Alberta Health
Care Insurance Plan, which is estimated to cover over 99% of the population. Each person is
assigned a personal health number that acts as a unique lifetime identifier (ULI) that is cap-
tured during health system encounters. This allows for deterministic linkage of data at the
individual level, across the basket of services available.
The data used in this study were released in aggregate from the Ministry of Health of
Alberta, and it’s use is covered by s. 26, meaning formal ethics was not required to access the
data. We used routinely collected data, analysed anonymously, and individual patient consent
was not required.
Alberta has a population-based, province-wide, discharge abstracts database which includes
all inpatient hospitalizations, ambulatory (outpatient) hospital visits, and emergency depart-
ment visits for patients of all ages. The province also maintains a comprehensive physician
claims database which captures all physician visits, regardless of service location or setting.
Diagnosis was extracted from the ICD 9 or ICD 10 codes provided as part of a hospital (inpa-
tient, outpatient, and emergency department) or physician visit. In order to do this an
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algorithm was applied and this is described elsewhere [14, 15]. Bernatsky and colleagues
showed that the data can be used, when an algorithm is applied, to improve specificity [15].
What this means for this study is that those we classified have a high probability of being accu-
rately assigned. The lower sensitivity suggests we are underestimating the number of cases. In
practice this means we are erring on misclassifying cases as non-cases, so are providing conser-
vative estimates of the cost differential. However, there was no specific information available
on the administrative data that speaks to which tests were used during a specific visit. Physi-
cian may code up to three diagnoses per encounter, while up to 25 are captured for inpatient
stays, and up to 10 for ambulatory or emergency department services. Individuals were classi-
fied as having SLE if they had at least three physician services over a two year period, with a
minimum of 60 days between the first and second services, or one or more hospitalizations [4,
16].
Health care resource use and direct healthcare costs of SLE and non-SLE cases were deter-
mined from inpatient hospital services, fee-for-physician services, emergency department ser-
vices, and ambulatory care services. All costs were estimated for calendar year or financial year
of 2016, and were estimated at the ULI level. The net fee paid to physicians was tabulated
directly from adjudicated physician claims data. Because patient-event level case costing is
only available for a portion of inpatient, ambulatory, and emergency visits, groupers were used
to estimate the cost of these events. For ambulatory and emergency visits, the Comprehensive
Ambulatory Classification System (CACS) grouper, developed by the Canadian Institute for
Health Information (CIHI), was used to link a Resource Intensity Weight (RIW) to each event.
The Cost per Weighted Case (CPWC, estimated with available case costing data) is applied to
RIW values to estimate the cost associated with each event. A similar process was used to esti-
mate the costs of inpatient events, using the RIW from the CIHI Case Mix Grouper Plus
(CMG+) methodology, and the costs of a Standard Hospital Stay (CSHS). Inpatient cost esti-
mates were pro-rated on an average per diem basis for events that began before Jan 1, 2016 or
ended after December 31, 2016.
Descriptive statistics were used to describe the characteristics of cases with SLE and non-
SLE. Summary statistics such as percentages and mean were presented.
Results
The demographic characteristics of the participants included in this study are summarized
(Table 1). A total number of 10,932 (Male = 2,546; Female = 8,386), and 4,185,136
(Male = 2,115,776; Female = 2,069,360) of SLE and non-SLE cases, respectively were included
in this study. Of these, 328 (Male = 124; Female = 204) and 1,038,088 (Male = 530,666,
Female = 507,422) cases of SLE and non SLE, respectively were below the age of 20 years. The
highest and lowest percentages of SLE cases included in this study were patients� 60 years
and< 20 years of age, respectively. For both male and female participants, the number of cases
of SLE increased with age.
The mean (SD) costs of SLE, and non-SLE per case are presented in Tables 2 and 3. The
mean (SD) costs of SLE, and non-SLE per case were $7,981 (4,499) (Male = $7,192 (3,931);
Female = $8,770(4989)), and $3,590 (3,204) (Male = $3,905 (3,647); Female = $3,276 (2761)),
respectively. The mean costs of SLE per case were $4,391 higher than the non-SLE. The mean
(SD) costs of fee-for-physician services (SLE = $1,960 (770); non-SLE = $1,069 (678)), inpa-
tient hospital services (SLE = $3,911 (3338); non-SLE = $1,721 (2130)), emergency services
(SLE = $472 (226); non-SLE = $220 (131)), and ambulatory care services (SLE = $1,637 (595);
non-SLE = $580 (380)) per case were estimated. The key cost drivers for the direct health care
costs of SLE were inpatient hospital services (49%).
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The annual costs of SLE and non-SLE per cases and non-cases by age group and service of
care are presented in Table 4. For both cases of SLE and non-SLE, the annual costs incurred
for fee-for physician services, inpatient hospital services, emergency department services and
ambulatory care services increased with age. Those� 60 years of age contributed the highest
percentages of costs that is fee-for physician services (48%); inpatients hospital services (58%),
emergency department services (46%) and ambulatory services (44%) due to SLE. Although
costs incurred by each services of care increased with age in both SLE and non-SLE, the share
of those� 60 years of age to the total costs was higher for the SLE compared to non-SLE.
The annual costs of SLE per total number of cases were estimated $84,615,150. Of this total
costs, fee-for physician services, inpatient services, emergency department services, and ambu-
latory care services were $23,613,224, $37,855,724, $4,813,060, and $18,333,143, respectively.
Overall, as people age, they are more likely to be hospitalized and that is the highest cost driver
for SLE in this study.
Discussion
We have provided estimates for direct health care costs associated with SLE and non-SLE in a
publicly funded, single payer system in the province of Alberta, Canada using real-world data.
The costs of SLE and non-SLE were estimated from a publicly funded and universally available
health care system in Alberta. The findings of this study suggest that, the mean (SD) costs esti-
mate of SLE per year was Can$7,981 (4,499) which are two times higher than those of non-
SLE. The mean costs per case of fee-for physician services, inpatient hospital services, emer-
gency department services, and ambulatory care services of SLE were 1.8, 2.3, 2.1, and 2.8 fold
greater compared to those of non-SLE, respectively. Moreover, the annual costs of SLE per
total number of cases in Alberta were estimated at Can$84,615,150.
Further, the findings of our study showed that the highest costs among the SLE case were in
older age group. The reason for this is that people with SLE could stay more expensive
throughout their life course due to related comorbidities [17]. This is consistent with Kang
Table 1. Characteristics of the participants.
Age (years) Number of cases with SLE Number of cases without SLE
Male Female All % Male Female All %
< 20 124 204 328 3.0 530,666 507,421 1,038,088 24.8
20–39 413 1,462 1,876 17.0 662,974 629,384 1,292,358 30.8
40–59 952 3,380 4,333 39.6 575,256 552,726 1,127,982 27.0
� 60 1,057 3,339 4,396 40.0 346,880 379,829 726,708 17.4
Total 2,546 8,386 10,932 2,115,776 2,069,360 4,185,136
https://doi.org/10.1371/journal.pone.0251409.t001
Table 2. Mean costs for SLE and Non SLE per case.
Variable SLE (Can$), Mean (SD) Non SLE (Can$), Mean (SD) P value
MD 1,960 (770) 1,069 (678) < 0.001
INPT 3,911 (3338) 1,721 (2130) < 0.001
EMRG 472 (226) 220 (131) < 0.001
AMB 1,637 (595) 580 (380) < 0.001
Total 7,981 (4,499) 3,590 (3,204) < 0.001
MD = Fee-for-physician services; INPT = Inpatient hospital services; EMRG = Costs attributed to emergency
department services; AMB = Ambulatory care services, or outpatient services provided by an acute care facility
https://doi.org/10.1371/journal.pone.0251409.t002
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et al. who suggested the presence of comorbidities such as nephropathy in SLE patients had
significantly higher total expenses for hospitalization during the end of life [18]. As people age,
they are more likely to be hospitalized and that was the highest cost driver in the system.
Therefore, even if SLE wasn’t causing a lot of grief, it could lead to a slightly longer hospital
stay and therefore increase healthcare costs with age. The increased costs in the older popula-
tion is more likely a function of an increased risk of hospitalization, rather than something
Table 3. Costs of SLE and non SLE per case by sex.
Variable Male Female
SLE (Can$), Mean (SD) % Non SLE (Can$), Mean (SD) % SLE (Can$), Mean (SD) % Non SLE (Can$),
Mean (SD)
%
MD 1,897 (790) 26 1,124 (727) 29 2,024 (766) 23 1,014 (642) 31
INPT 3,264 (2,802) 46 1,949 (2,529) 50 4,558 (3,768) 52 1,492 (1,683) 46
EMRG 452 (181) 6 233 (156) 6 492 (268) 6 207 (105) 6
AMB 1,579 (565) 22 598 (376) 15 1,694 (634) 19 561 (393) 17
Total 7,192 (3,931) 3,905 (3,647) 8,770 (4,989) 3,276 (2,761)
MD = Fee-for- physician services; INPT = Inpatient hospital services; EMRG = Costs attributed to emergency department services; AMB = Ambulatory care services, or
outpatient services provided by an acute care facility.
https://doi.org/10.1371/journal.pone.0251409.t003
Table 4. Annual costs of SLE and Non SLE per total number of cases/individual case by age group and service of care.
Variable SLE (Can$)/N (%) SLE (Can$)/individual case Non SLE (Can$)/N (%) Non SLE (Can$)/individual case
MD
< 20 344,965.75 (1) 1053.14 443,156,046.36 (13) 426.90
20–39 3,343,537.16 (14) 1782.50 859,841,017.00 (24) 665.33
40–59 8,585,826.06 (36) 1981.71 993,070,933.62 (28) 880.40
� 60 11,338,894.81(48) 2579.33 1,221,715,952.75 (35) 1681.16
Total 23,613,223.78 7396.68 3,517,783,949.73 3653.78
INPT
< 20 533,498.89 (1) 1628.71 436,269,206.92 (10) 420.26
20–39 4,123,147.99 (11) 2198.12 678,043,613.05 (16) 524.66
40–59 11,058,824.3 (29) 2552.51 878,414,123.53 (21) 778.75
� 60 22,140,252.6 (58) 5036.38 2,222,935,530.2 (53) 3058.91
Total 37,855,723.80 11415.72 4,215,662,473.78 4782.58
EMRG
< 20 123,805.86 (3) 377.97 138,339,975.1 (19) 133.26
20–39 837,429.99 (17) 446.45 205,707,030.6 (28) 159.17
40–59 1,618,961.26 (34) 373.68 180,600,280.5 (24) 160.11
� 60 2,232,862.6 (46) 507.92 214,659,171.3 (29) 295.39
Total 4,813,059.69 1706.01 739,306,457.55 747.93
AMB
< 20 422,155.34 (2) 1288.79 281,730,978.15 (15) 271.39
20–39 2,928,289.5 (16) 1561.12 358,457,164.2 (19) 277.37
40–59 6,988,613.5 (38) 1613.06 546,915,349.08 (29) 484.86
� 60 7,994,084.13 (44) 1818.46 717,327,631.2 (38) 987.09
Total 18,333,142.45 6281.43 1,904,431,122.69 2020.71
MD = Fee-for- physician services; INPT = Inpatient hospital services; EMRG = Costs attributed to emergency department services; AMB = Ambulatory care services, or
outpatient services provided by an acute care facility; N = Total number of cases.
https://doi.org/10.1371/journal.pone.0251409.t004
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specific to SLE. That said, that fact that our SLE cohort are more expensive at the higher ages
suggest that SLE could increase the risk of comorbidity, length of stay in hospital, or the likeli-
hood of being hospitalized for some other condition.
The findings of the current study were compared with previous studies that examined the
direct costs of SLE [13, 19, 10, 9, 11] and other types of disease such as rheumatoid arthritis
[20] in Canada and other countries. The results of the current study are very similar to those of
Clarke and colleagues (Can$7,832.0) that have used 164 patients with SLE in Canada [13]. The
direct cost in this study contained all resources utilized in patients’ care including ambulatory
care, hospital care, and rehabilitation facility care. Another study that estimated the direct
costs from 231 patients of SLE in Canada claimed that the mean annual direct costs of SLE was
Can$4968.0 [10]. A review of 24 studies from eight different countries including Canada esti-
mated the direct costs of rheumatoid arthritis (RA) per patient per year between $3,400 and
$21,000 [20]. The estimate of the direct costs SLE in the current study was twice of the lowest
estimate of RA. Parallel to this, the cost associated with inpatient care was the highest contribu-
tor of direct costs in both SLE (46%) and RA (75%) [20].
The direct costs estimate of SLE of the current study have shown a substantial variation
compared to China (US$8,230.0), USA (US$13,305.0), and Germany (€3,191.0) and the
United Kingdom (£2,613.0) [19, 20, 9, 11]. The direct cost estimate of SLE in the USA [21]
were approximately 50% higher than the cost estimates in our study. One of the explaining fac-
tor for this could be the patients included in the USA’s study, they were from US commercial
insurance claims database and were required to have� 2 claims and should have continuous
health plan enrolment for six months. Our direct cost estimates were 2 times higher than those
in the United Kingdom after making correction to currency and inflation adjustment [11].
Overall, the methodologies used to conduct the studies including the types of resource used
and the differences in the fee charged for healthcare in different countries may be the sources
of variation for the direct cost estimates due to SLE.
The healthcare utilization estimates in our study were also compared with previous studies
[13, 9, 19, 10, 21]. The costs estimate inpatient hospital service in our study were 1.3, 2.0, and
1.1 times of the Clarke et al. [13], Huscher et al. [9], and Pelletier et al. [20], respectively. The
cost estimates of the emergency department service in Alberta have been shown to be 3.6 fold
of the UK, and approximately identical to USA [11, 10]. The fee-for-physician services cost
estimate in the current study was found to be approximately 50% lower in the USA [10, 21].
One of the strengths of this study was that it has used a large number of cases with SLE and
non-SLE to determine the mean annual direct costs. This has enabled the researchers to esti-
mate the costs of the healthcare utilization including fee-for-physician services, inpatient hos-
pital services, emergency department services, and ambulatory care services from
comprehensive information. Compared with the cost estimates derived from surveys, the
direct costs estimate in our study is more reliable and generalizable. On the other hand, the
present study may have inadequately identified all patients with SLE in Alberta, this may be
due to the huge difference of the prevalence of SLE observed between the 2015 and 2016 calen-
dar years [4]. Another limitation of this study was that we did not cost the prescription of
drugs; this may underestimate the difference between those with SLE and those without. Over-
all, the authors believe that the annual direct cost estimate of SLE per case may have been
underestimated due to the inadequate identification of patients with SLE.
Conclusion
This is the first study to examine the direct health care costs of SLE, compared to non-SLE
cases in the real-world. Individuals with SLE, when compared to those without, incurred, on
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average, three times greater direct health system costs. These findings highlight the importance
of appropriate treatment and management to improve the health outcomes of patients with
SLE and reduce the healthcare utilization associated with the management of the condition.
Additional work is warranted to examine the overall costs of managing SLE and the specific
cost drivers which may be avoidable, or better managed, in the future. For example, do SLE
patients become more costly as they age and is this increase at a rate of growth that is different
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